Compositions comprising bacterial strains
The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.
1. A method of treating a systemic condition in a subject characterized by elevated levels of Escherichia coli ( E. coli ) in a tissue or organ in need thereof, comprising administering to said subject a pharmaceutical composition that comprises at least 1×10 3 colony forming units (CFU) per gram of a bacteria strain of the genus Blautia with respect to a total weight of said pharmaceutical composition, wherein said bacteria strain comprises a 16S rRNA gene having at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein said administering is effective to treat said systemic condition in said subject.
2. The method of claim 1 , wherein said systemic condition is a urinary tract infection.
3. The method of claim 1 , wherein said pharmaceutical composition comprises from about 1×10 3 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.
4. The method of claim 1 , wherein said pharmaceutical composition comprises from about 1×10 9 to about 1×10 12 CFU of said bacteria strain.
5. The method of claim 1 , further comprising administering an antibiotic treatment.
6. The method of claim 5 , wherein said administering of said antibiotic treatment is concurrent with said administering of said pharmaceutical composition.
7. The method of claim 5 , wherein said antibiotic is fluoroquinolone, azithromycin, ciprofloxacin or rifaximin.
8. The method of claim 1 , further comprising performing dehydration therapy to said subject.
9. The method of claim 1 , wherein said subject is a human.
10. The method of claim 1 , wherein said administering of said pharmaceutical composition is oral.
11. The method of claim 1 , wherein said administering of said pharmaceutical composition is rectal.
12. The method of claim 11 , wherein said pharmaceutical composition is formulated as a suppository.
13. The method of claim 12 , wherein said suppository comprises cocoa butter, suppocire, witepsol, glycero-gelatin, polyethylene glycol, or soap glycerin.
14. The method of claim 1 , wherein said bacteria strain is dried.
15. The method of claim 1 , wherein said pharmaceutical composition further comprises a lyoprotectant.
16. The method of claim 1 , wherein said pharmaceutical composition further comprises an enteric coating.
17. The method of claim 1 , wherein said pharmaceutical composition is a capsule formulation.
18. The method of claim 1 , wherein said bacteria strain is of the species Blautia hydrogenotrophica.